Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000780174 | SCV000917223 | likely benign | not specified | 2019-08-28 | criteria provided, single submitter | clinical testing | |
Invitae | RCV001272209 | SCV001673790 | likely benign | Cystic fibrosis | 2023-07-25 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV001272209 | SCV004055981 | likely benign | Cystic fibrosis | 2023-07-27 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Natera, |
RCV001272209 | SCV001453960 | uncertain significance | Cystic fibrosis | 2020-03-11 | no assertion criteria provided | clinical testing |